|
|
|
Drug Regimen
ZDV Monotherapy
Pharmacokinetics
Abstract: Systemic Pharmacokinetics (PK) of Oral Zidovudine (ZDV) Given during Labor and Delivery to HIV-1-Infected Pregnant Women [Abstract 660]
Abstract: Association of Maternal ZDV Use during Pregnancy and infant ZDV Genotypic Resistance with Rapid Disease Progression among Infants in the WITS [Abstract 709]
ZDV vs NVP
Efficacy
Abstract: A Randomized Trial of Single Dose Nevirapine to Mother and Infant Versus Azidothymidine in Kampala, Uganda for Prevention of Mother-to-Infant Transmission of HIV-1 (HIVNET 012). [Abstract S12]
ZDV/NFV/3TC
Efficacy, Pharmacokinetics, and Safety
Abstract: PACTG 353 A Phase I Study of Safety, Pharmacokinetics, and Antiviral Activity of Combination Nelfinavir (NFV), ZDV, and 3TC in HIV-Infected Pregnant Women and Their Infants [Abstract 715]
Drug Regimen
ZDV/ABC/3TC
Efficacy
Abstract: A Pilot Study of Early Therapy with Abacavir (ABC)/3TC/ZDV in HIV-1-Infected Infants [Abstract 700]
Drug Regimen
Combivir (ZDV/3TC)/NVP or NFV
Efficacy
Abstract: Preliminary Results of a Randomized Multicenter Study Comparing Combivir (ZDV/3TC) plus Nelfinavir or Nevirapine in HIV-Infected Naive Patients (COMBINE Study) [Abstract 510]
ZDV/ NVP/ABV/IDV/ 3TC
Pharmacokinetics
Abstract: Drug Levels and HIV-1 RNA in Serum and CSF during Treatment with a Five-Drug Regimen: AZT, 3TC, Abacavir, Nevirapine (NVP), and Indinavir (IDV) [Abstract 309]
Adverse Outcomes
Adverse Outcomes: General
Teratogenic ConsequencesAbstract: Antepartum Antiretroviral Therapy and Pregnancy Outcomes in 462 HIV-Infected Women in 1998-1999 (PACTG 367) [Abstract 664]
Assessing the Teratogenic Potential of Antiretroviral Drugs: Data from the Antiretroviral Pregnancy Registry [Abstract 68] Mitochondrial ToxicityAbstract:
Mitochondrial Toxicity of Perinatally Administered Zidovudine. Clinical Management Strategies [Abstract S14]Abstract:
 7th Conference on Retroviruses and Opportunistic Infections Conference Index Page: Zidovudine © 2000 Medical Advocates
for Social Justice |
